NIMG-17. VALIDATION OF DIFFUSION MRI AS AN IMAGING BIOMARKER FOR BEVACIZUMAB THERAPY IN RECURRENT GLIOBLASTOMA IN A RANDOMIZED PHASE III TRIAL OF BEVACIZUMAB WITH OR WITHOUT VB-111 (GLOBE)

BACKGROUND: Evidence from independent single center as well as multicenter phase II trials have suggested diffusion MRI is a strong predictive imaging biomarker for survival benefit in recurrent glioblastoma (rGBM) treated with anti-VEGF monotherapy, but not systemic chemotherapies or combination th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Ellingson, Benjamin, Cloughesy, Timothy, Wang, Chencai, Patel, Kunal, Raymond, Catalina, Brenner, Andrew, de Groot, John, Butowski, Nicholas, Zach, Leor, Campian, Jian, Schlossman, Jacob, Rizvi, Shan, Cohen, Yael, Lowenton-Spier, Noa, Minei, Tamar Rachmilewitz, Fain-Shmueli, Shifra, Wen, Patrick
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Neuroimaging
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651187/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.630
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados